Sample Testing. For the PCV Program, Moderna shall provide samples of biological material collected from subjects participating in a Clinical Study performed under the POC Plan for the PCV Program, including blood and/or tissue samples, to Merck as specified in the applicable protocol or as agreed to by the POC Committee.
Sample Testing. 8.1 The Grower shall during the harvest of the Crop obtain a 2 kilogram sample which is truly representative of the whole of the Crop (‘the Sample’).
8.2 The Grower shall ensure that as soon as possible following harvest of the Crop, and in any event no later than 31 March 2020, the Sample is received by Champion Flour Milling Ltd for testing. On receipt of the Sample, Champion Flour Milling Ltd will test the Sample using the procedure specified in Schedule 5. The cost to be for the growers account. The Grower must keep the Sample for three months following delivery of the entire Crop in accordance with this agreement.
8.3 Should artificial drying of the Crop be needed, the Sample taken for testing must be representative of the whole crop after drying has been undertaken and the Sample is to be labelled accordingly.
8.4 Champion Flour Milling Ltd shall immediately notify the Merchant of the results of testing of the Sample.
8.5 In the event that the Grower does not submit a Sample in accordance with clause 8.2, or if the Sample submitted does not meet the Quality Specifications set out in Schedule 1, Champion Flour Milling Ltd may, in accordance with clause 10.1, reject the Crop (or any part of it) to which the Sample relates, or would relate had a Sample been provided.
Sample Testing. 3.7.1. Company shall provide Samples to Merck as specified in the Protocol or as agreed to by the Joint Development Committee. Each Party shall (a) use the Samples only for the Sample Testing and (b) conduct the Sample Testing solely in accordance with the Data Sharing and Sample Testing Schedule and the Protocol.
3.7.2. Merck shall own all Sample Testing Results arising from Sample Testing performed by or on behalf of Merck. Solely to the extent specified on the Data Sharing and Sample Testing Schedule as being shared, Merck shall provide to Company the Sample Testing Results for the Sample Testing conducted by or on behalf of Merck, in electronic form or other mutually agreeable alternate form, on the timelines specified in the Data Sharing and Sample Testing Schedule or as otherwise mutually agreed.
3.7.3. Company shall own all Sample Testing Results arising from Sample Testing performed by or on behalf of Company. Solely to the extent specified on the Data Sharing and Sample Testing Schedule as being shared, Company shall provide to Merck the Sample Testing Results for the Sample Testing conducted by or on behalf of Company, in electronic form or other mutually agreeable alternate form, on the timelines specified in the Data Sharing and Sample Testing Schedule or as otherwise mutually agreed.
3.7.4. Except to the extent otherwise agreed in a writing signed by authorized representatives of each Party, each Party may use and disclose the Sample Testing Results owned by the other Party and shared by such other Party in accordance with the Data Sharing and Sample Testing Schedule solely for the purposes of [*****].
Sample Testing. 9.1. On completion of the harvest, and in any event no later than 30th April of the year of harvest, the Grower will supply a harvest sample of each line of Crop to the Purchaser.
9.2. Each submitted sample must be a minimum of 2 kg and be fully representative of no more than 200 tonne of grain.
9.3. The Purchaser will keep the Sample for three months following delivery of the entire Crop in accordance with this agreement.
9.4. Should artificial drying of the Crop be needed, the Sample taken for testing must be representative of the whole crop after drying has been undertaken, and the Sample is to be labelled accordingly.
9.5. In the event that the Grower does not submit a Sample in accordance with clause 9.1, or if the Sample submitted does not meet the Quality Specifications set out in Schedule 1, the Purchaser may, in accordance with clause 11, reject the Crop (or any part of it) to which the Sample relates, or would relate had a Sample been provided
Sample Testing. 3.8.1. Collaborator shall provide Samples to MSD as specified in the Protocol and as agreed to by the Joint Development Committee. Each Party shall use the Samples only for Sample Testing in accordance with the Sample Testing Schedule and the Protocol. [***].
3.8.2. Except to the extent otherwise expressly agreed, each Party may use and disclose the Sample Testing Results owned by and shared by the other Party in accordance with the Sample Testing Schedule solely for the purposes of: [***].
Sample Testing. 9.1 GSK shall perform or have performed all Sample Testing and shall own all Samples and Sample Testing Results.
9.2 GSK shall perform Sample Testing (a) of Biomarkers to the Sub-Study as set out in the applicable protocol and, (b) in relation to other Clinical Studies conducted under the Development Plan, as may be agreed between the Parties, acting through the JDC and
9.3 SpringWorks shall identify to GSK at the JDC its preferred vendor(s) for the conduct of bioanalytical testing relating to pharmacokinetic Samples from subjects in any Clinical Study conducted under the Development Plan, as provided in the relevant protocol for such Clinical Study (the “Bioanalytical Testing”). GSK shall use reasonable efforts to use such preferred vendor(s) for the Bioanalytical Testing, provided that such vendor(s) are approved in accordance with GSK’s internal due diligence processes and acceptable to GSK’s procurement and/or third party resourcing functions, as applicable (“Approved Vendor(s)”). [***]. Unless otherwise agreed and set out in the Development Plan, the Bioanalytical Testing shall be conducted [***] and GSK shall be responsible for overseeing the conduct of such testing by the Approved Vendor(s). SpringWorks shall:
(a) provide the necessary authorization for the Approved Vendor(s) to conduct the Bioanalytical Testing on behalf of GSK and for the delivery of the results of such testing to GSK so that the results may be included in the CSR, and (b) authorize the Approved Vendor(s) to provide GSK with access to the validation report and method for the analysis of the SpringWorks Compound, in the case of both (a) and (b), no later than [***] days following the engagement of such Approved Vendor. 10. PHARMACOVIGILANCE AGREEMENT. Within [***] days of the Effective Date, the Parties shall review the Pharmacovigilance Agreement and, to the extent necessary, shall update and amend such Pharmacovigilance Agreement to ensure the exchange of relevant safety data within appropriate timeframes and in appropriate format to enable the Parties to fulfil local and international regulatory reporting obligations and to facilitate appropriate safety reviews in relation to the activities to be conducted under this Agreement. In the event of a conflict between this Agreement and the Pharmacovigilance Agreement, the terms of the Pharmacovigilance Agreement shall control in relation to pharmacovigilance issues (including exchange of safety data) only. The Parties may enter into ...
Sample Testing. Seller may at its sole option, but is not obligated to, perform adequate testing to assure that shipped Products meet Buyer's sample testing criteria established in Attachment D. Notwithstanding the foregoing, prior to Seller initiating the volume manufacture of Products, Buyer shall have the right at its sole option, but is not obligated to, conduct sample testing of incoming Products and to reject lots that fail to meet the applicable product specifications and quality levels set forth in this Agreement and Attachments hereto (including the quality levels set forth in Attachment D), and/or US regulatory requirements and US law. Buyer shall have the right to conduct such testing either at Seller's manufacturing facility ("on-site testing") or Buyer's facility ("off-site testing"). Neither Buyer's waiver of its right to conduct sample testing nor Buyer's conducting sample testing in any way other than as set forth in Attachment D shall derogate from or otherwise affect in any way Buyer's other rights or remedies under this Agreement, including by illustration and not limitation its rights and remedies under sections 13, 14, or 17.
Sample Testing. 3.7.1. Company shall provide Samples to MSD as specified in the Protocol or as agreed to by the Joint Development Committee. Each Party shall (a) use the Samples only for the Sample Testing and (b) conduct the Sample Testing solely in accordance with the Sample Testing Schedule and the Protocol.
3.7.2. [***].
3.7.3. [***].
3.7.4. Except to the extent otherwise agreed in a writing signed by authorized representatives of each Party, each Party may use and disclose the Sample Testing Results owned by the other Party and shared by such other Party in accordance with the Sample Testing Schedule solely for the purposes of [***].
Sample Testing. Sample testing of products serves to provide evidence before the start of the series that required qual- ity control standards as designated in the drawings and specifications have been achieved. Sample testing is carried out in accordance with PPAP or VDA 2 / PPF. The procedure and submission level to be applied will be agreed with the supplier.
Sample Testing. 3.7.1. Intensity shall provide Samples to MSD as specified in the Protocol or the Sample Testing Schedule, or as agreed to by the Joint Development Committee. Each Party shall (a) use the Samples only for the Sample Testing and (b) conduct the Sample Testing solely in accordance with the Sample Testing Schedule and the Protocol.
3.7.2. [***]
3.7.3. [***].
3.7.4. Except to the extent otherwise agreed in a writing signed by authorized representatives of each Party, each Party may use and disclose the Sample Testing Results owned by the other Party and shared by such other Party in accordance with the Sample Testing Schedule solely for the purposes of [***].
